肿瘤防治研究2026，Vol.53Issue(5)：360-365,6.DOI:10.3971/j.issn.1000-8578.2026.26.0098
婴儿期神经母细胞瘤临床治疗及预后分析
Therapeutic Strategies and Prognosis of Neuroblastoma in Infants
张婷 1黄灿 1蒋莎义 1杨静薇 1廖雪莲 1邵静波1
作者信息
- 1. 200062 上海,上海市儿童医院,上海交通大学医学院附属儿童医院血液肿瘤科
- 折叠
摘要
Abstract
Objective To summarize the clinical characteristics and analyze prognostic factors of neuroblastoma(NB)in infants(≤12 months)at a single center.Methods A retrospective analysis was conducted on the clinical data of infant patients(≤12 months)diagnosed with NB and treated between January 2014 and December 2022.Clinical features were analyzed,and comparisons between two sample rates were performed using the χ2 test.Univariate prognostic analysis was conducted using the log-rank test,and survival outcomes were analyzed using the Kaplan-Meier method.Results A total of 42 infants(≤12 months)with NB were enrolled.Low-risk patients underwent surgical resection alone;intermediate-risk patients received surgery combined with chemotherapy with or without maintenance therapy;high-risk patients were treated with surgery and chemotherapy with or without maintenance therapy or radiotherapy.The 5-year event-free survival(EFS)rate was(92.7±4.9)%,and the 5-year overall survival rate was(95.2±3.6)%.Only two patients died because of tumor recurrence or progression.Univariate analysis identified MYCN amplification and the initial lactate dehydrogenase(LDH)level≥five times the upper limit of the normal were significantly associated with poor prognosis(5-year EFS:33.3%vs.97.4%and 60.0%vs.97.3%,P<0.000 1 and P=0.003 5).Conclusion Infant NB has a favorable overall prognosis.MYCN ampli-fication and markedly elevated initial LDH are associated with poor outcomes.关键词
神经母细胞瘤/婴儿期/危险因素/预后Key words
Neuroblastoma/Infant period/Risk factor/Prognosis分类
医药卫生引用本文复制引用
张婷,黄灿,蒋莎义,杨静薇,廖雪莲,邵静波..婴儿期神经母细胞瘤临床治疗及预后分析[J].肿瘤防治研究,2026,53(5):360-365,6.
